The strategies aimed at reducing UHRF1 activity in retinoblastoma cells enhance sensitivity to HDAC inhibitors, offering another potential therapeutic approach by exploiting the interplay between HDACs and UHRF1 in retinoblastoma progression. The gene discussed is UHRF1; the disease is retinoblastoma.